THE EUROPEAN MEDICINES AGENCY

Their core work

The European Medicines Agency is the EU's decentralized regulatory body responsible for evaluating, supervising, and monitoring medicines for human and veterinary use across Europe. In H2020 projects, EMA contributes its unique regulatory perspective — advising on adaptive clinical trial design, drug approval pathways, pharmacovigilance systems, and environmental risk assessment of pharmaceuticals. Their participation brings real-world regulatory authority to research consortia, ensuring that scientific outputs align with the frameworks governing drug development and market access in Europe.

What they specialise in

How they've shifted over time

EMA's early H2020 involvement (2015-2018) centered on streamlining drug development pathways — adaptive trial design, regulatory-HTA collaboration, and reimbursement models through ADAPT-SMART. From 2019 onward, their focus shifted markedly toward data-driven safety monitoring: pregnancy pharmacovigilance (ConcePTION), environmental impact of pharmaceuticals (PREMIER), and standardizing patient-reported outcomes (SISAQOL-IMI). This evolution reflects a regulatory body moving from process optimization toward evidence-based safety surveillance and environmental accountability.

EMA is expanding beyond traditional drug approval into environmental pharmacology and real-world evidence generation, signaling openness to consortia addressing pharmaceutical sustainability and post-market safety data.

How they like to work

EMA participates exclusively as a consortium partner, never as coordinator — consistent with its role as a regulatory authority contributing expertise rather than leading research execution. With 150 unique partners across 30 countries from just 5 projects, EMA joins very large consortia (averaging 30 partners per project), reflecting its institutional mandate to engage broadly across European research ecosystems. Their modest funding shares (avg EUR 37K) confirm an advisory and standards-setting role rather than hands-on research delivery.

EMA has collaborated with 150 unique partners across 30 countries through just 5 projects, reflecting its position at the center of Europe's pharmaceutical regulatory network. Their reach spans nearly all EU member states plus associated countries, making them one of the most broadly connected public bodies in H2020 health research.

What sets them apart

EMA is not a research organization — it is THE European regulatory authority for medicines, making its participation in a consortium an immediate signal of regulatory relevance and policy alignment. No other H2020 partner can provide the same direct line between research outputs and the actual frameworks governing drug approval, pharmacovigilance, and market access in Europe. For consortia seeking regulatory buy-in from the design phase rather than after the fact, EMA's involvement is uniquely valuable.

Highlights from their portfolio

• PREMIER
  EMA's largest funded project (EUR 47K) and a pioneering effort to integrate environmental risk assessment into pharmaceutical regulation — a rapidly growing policy area.
• ConcePTION
  A major pharmacovigilance ecosystem for medication safety in pregnancy, running until 2024, addressing a critical gap where most drugs lack safety data for pregnant women.
• ADAPT-SMART
  Flagship initiative on adaptive drug development pathways bringing together regulators, HTA bodies, and industry to redesign how therapies reach patients faster.